HC Wainwright Reiterates “Buy” Rating for AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $16.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 401.57% from the company’s current price.

Separately, StockNews.com downgraded shares of AC Immune from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st.

AC Immune Stock Performance

Shares of ACIU stock opened at $3.19 on Friday. The firm has a market cap of $315.62 million, a P/E ratio of -6.93 and a beta of 1.28. The firm’s 50 day moving average price is $3.28 and its 200-day moving average price is $3.49. AC Immune has a one year low of $2.25 and a one year high of $5.14.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its stake in AC Immune by 26.4% in the 2nd quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock valued at $2,602,000 after buying an additional 136,300 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in AC Immune by 294.7% in the second quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock valued at $1,755,000 after buying an additional 328,312 shares during the last quarter. BNP Paribas Financial Markets raised its stake in AC Immune by 315.6% during the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock valued at $33,000 after acquiring an additional 8,423 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in shares of AC Immune in the 1st quarter worth approximately $30,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of AC Immune by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after buying an additional 7,400 shares during the period. Institutional investors and hedge funds own 51.36% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.